Medical treatment of hyperadrenocorticism in the dog

Australian Veterinary Journal

Volumn 81, Issue 1-2, 2003, Pages 31-33

  Braddock, J A ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CANIS FAMILIARIS;

AMINOGLUTETHIMIDE; ANDROSTANOLONE; BROMOCRIPTINE; CYPROHEPTADINE; DRUG DERIVATIVE; ETOMIDATE; KETOCONAZOLE; METYRAPONE; MITOTANE; SELEGILINE; TRILOSTANE;

ADRENAL CORTEX HYPERFUNCTION; ANIMAL; ANIMAL DISEASE; DOG; DOG DISEASE; REVIEW;

ADRENOCORTICAL HYPERFUNCTION; AMINOGLUTETHIMIDE; ANIMALS; BROMOCRIPTINE; CYPROHEPTADINE; DIHYDROTESTOSTERONE; DOG DISEASES; DOGS; ETOMIDATE; KETOCONAZOLE; METYRAPONE; MITOTANE; SELEGILINE;

EID: 2342633824     PISSN: 00050423     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1751-0813.2003.tb11415.x     Document Type: Short Survey

References (36)

1. Watson ADJ, Rijnberk A, Moolenaar AJ. Systemic availability of o,p′-DDD in normal dogs, fasted and fed, and in dogs with hyperadrenocorticism. Res Vet Sci 1987;43:160-165.
2. Cai W, Counsell RE, Djanegara T et al. Metabolic activation and binding of mitotane in adrenal cortex homogenates. J Pharm Sci 1995;84:134-138.
3. Hart MM, Reagan RL, Adamson RH. The effect of isomers of DDD on the ACTH-induced steroid output, histology, and ultrastructure of the dog adrenal cortex. Toxicol Appl Pharmacol 1973;24:101-113.
4. Kintzer PP, Peterson ME. Mitotane (o,p'-DDD) treatment of 200 dogs with pituitary-dependent hyperadrenocorticism. J Vet Intern Med 1991;5:182-190.
5. Rijnberk A, Belshaw BE. An alternative protocol for the management of canine pituitary-dependent hyperadrenocorticism. Vet Rec 1988;122:486-488.
6. Peterson ME, Kintzer PP. Medical treatment of pituitary-dependent hyperadrenocorticism. Mitotane. Vet Clin N Am 1997;27:255-272.
7. Feldman EC, Nelson RW. Hyperadrenocorticism (Cushing's syndrome). In: Canine and Feline Endocrinology and Reproduction, 2nd edn. Saunders, Philadelphia, 1996:187-265.
8. Loose DS, Kan PB, Hirst MA, Marcus RA, Feldman D. Ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P450-dependent enzymes. J Clin Invest 1983;71:1495-1499.
9. Nagai K, Miyamori I, Ikeda M et al. Effect of ketoconazole (an imidazole antimycotic agent) and other inhibitors of steroidogenesis on cytochrome P450-catalysed reactions. J Steroid Biochem 1986;24:321-323.
10. Feldman EC, Bruyette DS, Nelson RW, Farver TB. Plasma cortisol response to ketoconazole administration in dogs with hyperadrenocorticism. J Am Vet Med Assoc 1990;197:71-78.
11. Legendre AM, Selcer BA, Edwards DF, Stevens R. Treatment of canine blastomycosis with amphotericin B and ketoconazole. J Am Vet Med Assoc 1984;184:1249-1254.
12. Janssen PA, Symoens JE. Hepatic reactions during ketoconazole treatment. Am J Med 1983;74:80-85.
13. Schulte HM, Benker G, Reinwein D, Sippell WG, Allolio B. Infusion of low dose etomidate: correction of hypercortisolaemia in patients with Cushing's syndrome and dose-response relationship in normal subjects. J Clin Endocrinol Metab 1990;70:1426-1430.
14. Lambert A, Mitchell R, Frost J, Ratcliffe JG, Robertson WR. Direct in vitro inhibition of adrenal steroidogenesis by etomidate. Lancet 1983;11:1085-1086.
15. Schteingart DE, Conn JW. Effects of aminoglutethimide upon adrenal function and cortisol metabolism in Cushing's syndrome. J Clin Endocrinol Metab 1967;27:1657-1666.
16. Schteingart DE. Cushing syndrome. In: Principles and Practice of Endocrinology and Metabolism, 2nd edn. JB Lippincott Company, Philadelphia. 1995;667-682.
17. 10] LHRH ethylamide, aminoglutethimide, ketoconazole, or flutamide alone or in combination on testicular, serum, adrenal and prostatic steroid levels in the dog. J Steroid Biochem 1989;33:233-242.
18. Castill V, Lalia J, Casal J et al. Aminoglutethimide: Therapeutic alternative in canines with Cushing's disease (hypophysis dependent). [Spanish]. Avan Cienc Vet 1996;11:93-96.
19. Thoren M, Adamson U, Sjöberg HE. Aminoglutethimide and metyrapone in the management of Cushing's syndrome. Acta Endocrinol 1985;109:451-457.
20. Orth DN, Kovacs WJ. Hyperfunction. Glucocorticoids: hypercortisolism (Cushing's syndrome). In: Williams textbook of endocrinology, 9th edn. Saunders, Philadelphia. 1998:565-595.
21. Verheist JA, Trainer PJ, Howlett TA et al. Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing's syndrome. Clin Endocrinol 1991;35:169-178.
22. Daley CA, Zerbe CA, Schick RO, Powers RD. Use of metyrapone to treat pituitary-dependent hyperadrenocorticism in a cat with large cutaneous wounds. J Am Vet Med Assoc 1993;202:956-960.
23. Moore LE, Biller DS, Olsen DE. Hyperadrenocorticism treated with metyrapone followed by bilateral adrenalectomy in a cat. J Am Vet Med Assoc 2000;217:691-694.
24. Potts GO, Creange JE, Harding HR, Schane HP. Trilostane, an orally active inhibitor of steroid biosynthesis. Steroids 1978;32:257-267.
25. Schane HP, Potts GO, Creange JE. Inhibition of ovarian placental and adrenal steroidogenesis in the rhesus monkey by trilostane. Fertil Steril 1979;32:464-467.
26. Hurley K, Sturgess K, Cauvin A, Kuipers R. The use of trilostane for the treatment of hyperadrenocorticism in dogs [abstract]. J Vet Intern Med 1998;12:210.
27. Ramsey IK, Hurley K. Use of trilostane in hyperadrenocorticism [abstract]. J Small Anim Pract 2000;41:373.
28. Neiger R, Hurley K. 24-hour cortisol values in dogs with hyperadrenocorticism on trilostane [abstract]. J Small Anim Pract 2001;42:376.
29. Braddock JA, Church DB, Robertson ID, Watson ADJ. Trilostane treatment in dogs with pituitary-dependent hyperadrenocorticism, submitted for publication.
30. Campbell S, Trettien A, Kozan B. A noncomparative open-label study evaluating the effect of selegiline hydrochloride in a clinical setting. Vet Therap 2001;2:24-39.
31. Bruyette DS, Ruehl WW, Entriken T, Griffin D, Darling L. Management of canine pituitary-dependent hyperadrenocorticism with I-deprenyl (Anipryl). Vet Clin N Am 1997;27:273-286.
32. Bruyette DS, Ruehl WW, Entriken TL, Darling LA, Griffin DW. Treating canine pituitary-dependent hyperadrenocorticism with L-deprenyl. Vet Med 1997;92:711-727.
33. Reusch CE, Steffen T, Hoerauf A. The Efficacy of L-deprenyl in dogs with pituitary-dependent hyperadrenocorticism. J Vet Intern Med 1999;13:291-301.
34. Braddock JA, Church DB, Robertson ID, Watson ADJ. Selegiline treatment in dogs with pituitary-dependent hyperadrenocorticism, submitted for publication.
35. Stolp R, Croughs RJM, Rijnberk A. Results of cyproheptadine treatment in dogs with pituitary-dependent hyperadrenocorticism. J Endocrinol 1984;101:311-314.
36. Rijnberk A, van Wees A, Mol JA. Assessment of two tests for the diagnosis of canine hyperadrenocorticism. Vet Rec 1988;122:178-180.